TriMaster: randomised double-blind crossover study of a DPP4 inhibitor, SGLT2 inhibitor and thiazolidinedione as second-line or third-line therapy in patients with type 2 diabetes who have suboptimal glycaemic control on metformin treatment with or without a sulfonylurea-a MASTERMIND study protocol. (2020)
Attributed to:
MICA: MRC APBI STratification and Extreme Response Mechanism IN Diabetes - MASTERMIND
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1136/bmjopen-2020-042784
PubMed Identifier: 33371044
Publication URI: http://europepmc.org/abstract/MED/33371044
Type: Journal Article/Review
Volume: 10
Parent Publication: BMJ open
Issue: 12
ISSN: 2044-6055